Merck（MERK）株式概要PT Merck Tbkは、インドネシア国内および海外で医薬品の製造・販売を行っている。 詳細MERK ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績6/6財務の健全性6/6配当金3/6報酬当社が推定した公正価値より93.5%で取引されている 過去1年間で収益は106.9%増加しました リスク分析不安定な配当実績 意味のある時価総額がありません ( IDR1,676B )すべてのリスクチェックを見るMERK Community Fair Values Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,712 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,712 investors already sharing narrativesYour Fair ValueRpCurrent PriceRp3.76k53.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16b1t2016201920222025202620282031Revenue Rp1.5tEarnings Rp340.7bAdvancedSet Fair ValueView all narrativesPT Merck Tbk 競合他社Darya-Varia LaboratoriaSymbol: IDX:DVLAMarket cap: Rp1.7tTempo Scan PacificSymbol: IDX:TSPCMarket cap: Rp11.3tSoho Global HealthSymbol: IDX:SOHOMarket cap: Rp15.4tPhaprosSymbol: IDX:PEHAMarket cap: Rp208.3b価格と性能株価の高値、安値、推移の概要Merck過去の株価現在の株価Rp3,760.0052週高値Rp4,500.0052週安値Rp2,720.00ベータ0.181ヶ月の変化7.43%3ヶ月変化3.58%1年変化28.77%3年間の変化-21.34%5年間の変化10.59%IPOからの変化1,254.96%最新ニュースお知らせ • May 30PT Merck Tbk announces Annual dividend, payable on June 24, 2026PT Merck Tbk announced Annual dividend of IDR 275.0000 per share payable on June 24, 2026, ex-date on June 08, 2026 and record date on June 09, 2026.Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp145 (vs Rp29.45 in 1Q 2025)First quarter 2026 results: EPS: Rp145 (up from Rp29.45 in 1Q 2025). Revenue: Rp283.1b (up 32% from 1Q 2025). Net income: Rp65.2b (up 394% from 1Q 2025). Profit margin: 23% (up from 6.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to Rp4,300, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 9x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 8.7% over the past three years.お知らせ • Apr 16PT Merck Tbk, Annual General Meeting, May 25, 2026PT Merck Tbk, Annual General Meeting, May 25, 2026.Reported Earnings • Apr 03Full year 2025 earnings released: EPS: Rp544 (vs Rp343 in FY 2024)Full year 2025 results: EPS: Rp544 (up from Rp343 in FY 2024). Revenue: Rp1.20t (up 16% from FY 2024). Net income: Rp243.9b (up 59% from FY 2024). Profit margin: 20% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp178 (vs Rp65.21 in 3Q 2024)Third quarter 2025 results: EPS: Rp178 (up from Rp65.21 in 3Q 2024). Revenue: Rp334.0b (up 18% from 3Q 2024). Net income: Rp79.6b (up 172% from 3Q 2024). Profit margin: 24% (up from 10% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.最新情報をもっと見るRecent updatesお知らせ • May 30PT Merck Tbk announces Annual dividend, payable on June 24, 2026PT Merck Tbk announced Annual dividend of IDR 275.0000 per share payable on June 24, 2026, ex-date on June 08, 2026 and record date on June 09, 2026.Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp145 (vs Rp29.45 in 1Q 2025)First quarter 2026 results: EPS: Rp145 (up from Rp29.45 in 1Q 2025). Revenue: Rp283.1b (up 32% from 1Q 2025). Net income: Rp65.2b (up 394% from 1Q 2025). Profit margin: 23% (up from 6.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to Rp4,300, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 9x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 8.7% over the past three years.お知らせ • Apr 16PT Merck Tbk, Annual General Meeting, May 25, 2026PT Merck Tbk, Annual General Meeting, May 25, 2026.Reported Earnings • Apr 03Full year 2025 earnings released: EPS: Rp544 (vs Rp343 in FY 2024)Full year 2025 results: EPS: Rp544 (up from Rp343 in FY 2024). Revenue: Rp1.20t (up 16% from FY 2024). Net income: Rp243.9b (up 59% from FY 2024). Profit margin: 20% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp178 (vs Rp65.21 in 3Q 2024)Third quarter 2025 results: EPS: Rp178 (up from Rp65.21 in 3Q 2024). Revenue: Rp334.0b (up 18% from 3Q 2024). Net income: Rp79.6b (up 172% from 3Q 2024). Profit margin: 24% (up from 10% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.Board Change • Oct 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 09PT Merck Tbk, Annual General Meeting, Jun 16, 2025PT Merck Tbk, Annual General Meeting, Jun 16, 2025.お知らせ • Feb 14PT Merck Tbk, Annual General Meeting, Mar 24, 2025PT Merck Tbk, Annual General Meeting, Mar 24, 2025. Location: jakarta IndonesiaNew Risk • Nov 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: Rp1.56t (US$98.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 107% Cash payout ratio: 123% Minor Risk Market cap is less than US$100m (Rp1.56t market cap, or US$98.2m).Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp52.20 (vs Rp101 in 2Q 2023)Second quarter 2024 results: EPS: Rp52.20 (down from Rp101 in 2Q 2023). Revenue: Rp221.7b (down 6.5% from 2Q 2023). Net income: Rp23.5b (down 48% from 2Q 2023). Profit margin: 11% (down from 19% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.New Risk • May 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.お知らせ • May 09PT Merck Tbk, Annual General Meeting, May 29, 2024PT Merck Tbk, Annual General Meeting, May 29, 2024. Location: kantor perseroan, jl. tb simatupang no. 8, pasar, rebo, jakarta 13760 dki. jakarta / kota adm., jakarta timur dki. jakarta indonesia, jakarta IndonesiaBuying Opportunity • Nov 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.4%. The fair value is estimated to be Rp5,477, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 19%.Buying Opportunity • Nov 08Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.8%. The fair value is estimated to be Rp5,477, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 19%.Reported Earnings • Nov 07Third quarter 2023 earnings released: EPS: Rp87.11 (vs Rp58.81 in 3Q 2022)Third quarter 2023 results: EPS: Rp87.11 (up from Rp58.81 in 3Q 2022). Revenue: Rp282.3b (up 4.7% from 3Q 2022). Net income: Rp39.0b (up 48% from 3Q 2022). Profit margin: 14% (up from 9.8% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Aug 03New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 97% Cash payout ratio: 102% Dividend yield: 6.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp101 (vs Rp136 in 2Q 2022)Second quarter 2023 results: EPS: Rp101 (down from Rp136 in 2Q 2022). Revenue: Rp237.1b (down 20% from 2Q 2022). Net income: Rp45.1b (down 26% from 2Q 2022). Profit margin: 19% (down from 20% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 06First quarter 2023 earnings released: EPS: Rp103 (vs Rp140 in 1Q 2022)First quarter 2023 results: EPS: Rp103 (down from Rp140 in 1Q 2022). Revenue: Rp261.1b (down 13% from 1Q 2022). Net income: Rp46.3b (down 26% from 1Q 2022). Profit margin: 18% (down from 21% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 24Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: Rp269.7b (down 3.4% from 3Q 2021). Net income: Rp26.3b (down 27% from 3Q 2021). Profit margin: 9.8% (down from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 17Full year 2021 earnings released: EPS: Rp294 (vs Rp160 in FY 2020)Full year 2021 results: EPS: Rp294 (up from Rp160 in FY 2020). Revenue: Rp1.06t (up 62% from FY 2020). Net income: Rp131.7b (up 83% from FY 2020). Profit margin: 12% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Dec 03Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: EPS: Rp80.91 (up from Rp51.23 in 3Q 2020). Revenue: Rp279.3b (up 78% from 3Q 2020). Net income: Rp36.2b (up 58% from 3Q 2020). Profit margin: 13% (down from 15% in 3Q 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 27New 90-day low: Rp3,000The company is down 2.0% from its price of Rp3,060 on 27 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: Rp3,340The company is up 6.0% from its price of Rp3,140 on 08 October 2020. The Indonesian market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 21New 90-day high: Rp3,320The company is up 15% from its price of Rp2,880 on 23 September 2020. The Indonesian market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.Is New 90 Day High Low • Nov 26New 90-day high: Rp3,280The company is up 1.0% from its price of Rp3,260 on 28 August 2020. The Indonesian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS Rp51.33The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: Rp157.0b (down 13% from 3Q 2019). Net income: Rp22.9b (up 110% from 3Q 2019). Profit margin: 15% (up from 6.0% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.株主還元MERKID PharmaceuticalsID 市場7D1.9%0.8%1.4%1Y28.8%-31.5%-18.7%株主還元を見る業界別リターン: MERK過去 1 年間で-31.5 % の収益を上げたID Pharmaceuticals業界を上回りました。リターン対市場: MERK過去 1 年間で-18.7 % の収益を上げたID市場を上回りました。価格変動Is MERK's price volatile compared to industry and market?MERK volatilityMERK Average Weekly Movement6.1%Pharmaceuticals Industry Average Movement7.8%Market Average Movement8.2%10% most volatile stocks in ID Market16.1%10% least volatile stocks in ID Market4.4%安定した株価: MERK 、 ID市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MERKの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1970362Evie Yulinwww.merckgroup.com/id-idPT Merck Tbk は、インドネシアおよび海外で医薬品の製造・販売を行っている。バイオファーマ事業、コンシューマーヘルス事業、その他事業を行っている。循環器、代謝、腫瘍、内分泌、不妊、神経変性疾患、一般医薬品の分野でヘルスケア製品を提供している。また、大腸がん、頭頸部がん、多発性硬化症、不妊症、成長ホルモン障害、糖尿病、甲状腺機能低下症などの甲状腺疾患を治療するための医薬品および生物学的処方薬の研究、開発、製造、販売にも取り組んでいる。また、オフィス・不動産の賃貸・管理事業にも携わっている。以前はPT Merck Indonesia Tbkとして知られ、2002年6月にPT Merck Tbkに社名を変更した。同社は1970年に設立され、インドネシアのジャカルタ・ティムールに拠点を置く。PT Merck Tbk は Merck Holding GmbH の子会社として運営されている。もっと見るPT Merck Tbk 基礎のまとめMerck の収益と売上を時価総額と比較するとどうか。MERK 基礎統計学時価総額Rp1.68t収益（TTM）Rp295.88b売上高(TTM)Rp1.27t5.7xPER（株価収益率1.3xP/SレシオMERK は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MERK 損益計算書（TTM）収益Rp1.27t売上原価Rp646.76b売上総利益Rp621.85bその他の費用Rp325.97b収益Rp295.88b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）660.45グロス・マージン49.02%純利益率23.32%有利子負債／自己資本比率0%MERK の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.5%現在の配当利回り43%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 15:29終値2026/07/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Merck Tbk 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 30PT Merck Tbk announces Annual dividend, payable on June 24, 2026PT Merck Tbk announced Annual dividend of IDR 275.0000 per share payable on June 24, 2026, ex-date on June 08, 2026 and record date on June 09, 2026.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp145 (vs Rp29.45 in 1Q 2025)First quarter 2026 results: EPS: Rp145 (up from Rp29.45 in 1Q 2025). Revenue: Rp283.1b (up 32% from 1Q 2025). Net income: Rp65.2b (up 394% from 1Q 2025). Profit margin: 23% (up from 6.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to Rp4,300, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 9x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 8.7% over the past three years.
お知らせ • Apr 16PT Merck Tbk, Annual General Meeting, May 25, 2026PT Merck Tbk, Annual General Meeting, May 25, 2026.
Reported Earnings • Apr 03Full year 2025 earnings released: EPS: Rp544 (vs Rp343 in FY 2024)Full year 2025 results: EPS: Rp544 (up from Rp343 in FY 2024). Revenue: Rp1.20t (up 16% from FY 2024). Net income: Rp243.9b (up 59% from FY 2024). Profit margin: 20% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp178 (vs Rp65.21 in 3Q 2024)Third quarter 2025 results: EPS: Rp178 (up from Rp65.21 in 3Q 2024). Revenue: Rp334.0b (up 18% from 3Q 2024). Net income: Rp79.6b (up 172% from 3Q 2024). Profit margin: 24% (up from 10% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
お知らせ • May 30PT Merck Tbk announces Annual dividend, payable on June 24, 2026PT Merck Tbk announced Annual dividend of IDR 275.0000 per share payable on June 24, 2026, ex-date on June 08, 2026 and record date on June 09, 2026.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: Rp145 (vs Rp29.45 in 1Q 2025)First quarter 2026 results: EPS: Rp145 (up from Rp29.45 in 1Q 2025). Revenue: Rp283.1b (up 32% from 1Q 2025). Net income: Rp65.2b (up 394% from 1Q 2025). Profit margin: 23% (up from 6.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 18%After last week's 18% share price gain to Rp4,300, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 9x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 8.7% over the past three years.
お知らせ • Apr 16PT Merck Tbk, Annual General Meeting, May 25, 2026PT Merck Tbk, Annual General Meeting, May 25, 2026.
Reported Earnings • Apr 03Full year 2025 earnings released: EPS: Rp544 (vs Rp343 in FY 2024)Full year 2025 results: EPS: Rp544 (up from Rp343 in FY 2024). Revenue: Rp1.20t (up 16% from FY 2024). Net income: Rp243.9b (up 59% from FY 2024). Profit margin: 20% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 04Third quarter 2025 earnings released: EPS: Rp178 (vs Rp65.21 in 3Q 2024)Third quarter 2025 results: EPS: Rp178 (up from Rp65.21 in 3Q 2024). Revenue: Rp334.0b (up 18% from 3Q 2024). Net income: Rp79.6b (up 172% from 3Q 2024). Profit margin: 24% (up from 10% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
Board Change • Oct 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 09PT Merck Tbk, Annual General Meeting, Jun 16, 2025PT Merck Tbk, Annual General Meeting, Jun 16, 2025.
お知らせ • Feb 14PT Merck Tbk, Annual General Meeting, Mar 24, 2025PT Merck Tbk, Annual General Meeting, Mar 24, 2025. Location: jakarta Indonesia
New Risk • Nov 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: Rp1.56t (US$98.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 107% Cash payout ratio: 123% Minor Risk Market cap is less than US$100m (Rp1.56t market cap, or US$98.2m).
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: Rp52.20 (vs Rp101 in 2Q 2023)Second quarter 2024 results: EPS: Rp52.20 (down from Rp101 in 2Q 2023). Revenue: Rp221.7b (down 6.5% from 2Q 2023). Net income: Rp23.5b (down 48% from 2Q 2023). Profit margin: 11% (down from 19% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.
New Risk • May 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
お知らせ • May 09PT Merck Tbk, Annual General Meeting, May 29, 2024PT Merck Tbk, Annual General Meeting, May 29, 2024. Location: kantor perseroan, jl. tb simatupang no. 8, pasar, rebo, jakarta 13760 dki. jakarta / kota adm., jakarta timur dki. jakarta indonesia, jakarta Indonesia
Buying Opportunity • Nov 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.4%. The fair value is estimated to be Rp5,477, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 19%.
Buying Opportunity • Nov 08Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.8%. The fair value is estimated to be Rp5,477, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 19%.
Reported Earnings • Nov 07Third quarter 2023 earnings released: EPS: Rp87.11 (vs Rp58.81 in 3Q 2022)Third quarter 2023 results: EPS: Rp87.11 (up from Rp58.81 in 3Q 2022). Revenue: Rp282.3b (up 4.7% from 3Q 2022). Net income: Rp39.0b (up 48% from 3Q 2022). Profit margin: 14% (up from 9.8% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 03New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 97% Cash payout ratio: 102% Dividend yield: 6.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: Rp101 (vs Rp136 in 2Q 2022)Second quarter 2023 results: EPS: Rp101 (down from Rp136 in 2Q 2022). Revenue: Rp237.1b (down 20% from 2Q 2022). Net income: Rp45.1b (down 26% from 2Q 2022). Profit margin: 19% (down from 20% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 06First quarter 2023 earnings released: EPS: Rp103 (vs Rp140 in 1Q 2022)First quarter 2023 results: EPS: Rp103 (down from Rp140 in 1Q 2022). Revenue: Rp261.1b (down 13% from 1Q 2022). Net income: Rp46.3b (down 26% from 1Q 2022). Profit margin: 18% (down from 21% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 24Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: Rp269.7b (down 3.4% from 3Q 2021). Net income: Rp26.3b (down 27% from 3Q 2021). Profit margin: 9.8% (down from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 1 independent director (2 non-independent directors). Plant Director & Independent Director Arryo Aritrixso Teguh Wachjuwidajat was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 17Full year 2021 earnings released: EPS: Rp294 (vs Rp160 in FY 2020)Full year 2021 results: EPS: Rp294 (up from Rp160 in FY 2020). Revenue: Rp1.06t (up 62% from FY 2020). Net income: Rp131.7b (up 83% from FY 2020). Profit margin: 12% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Dec 03Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: EPS: Rp80.91 (up from Rp51.23 in 3Q 2020). Revenue: Rp279.3b (up 78% from 3Q 2020). Net income: Rp36.2b (up 58% from 3Q 2020). Profit margin: 13% (down from 15% in 3Q 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 27New 90-day low: Rp3,000The company is down 2.0% from its price of Rp3,060 on 27 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: Rp3,340The company is up 6.0% from its price of Rp3,140 on 08 October 2020. The Indonesian market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 21New 90-day high: Rp3,320The company is up 15% from its price of Rp2,880 on 23 September 2020. The Indonesian market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Nov 26New 90-day high: Rp3,280The company is up 1.0% from its price of Rp3,260 on 28 August 2020. The Indonesian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS Rp51.33The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: Rp157.0b (down 13% from 3Q 2019). Net income: Rp22.9b (up 110% from 3Q 2019). Profit margin: 15% (up from 6.0% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
